The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Drug: omalizumab     Quarter: 2016Q3

Total Drug/Injury Combinations: 175     Number of Pages: 9

DRUGNAME PT EventCount
Omalizumab Red blood cell count increased 18 view events
Omalizumab Sense of oppression 18 view events
Omalizumab Sputum discoloured 18 view events
Omalizumab Varicose vein 18 view events
Omalizumab White blood cell count increased 18 view events
Omalizumab Exposure during pregnancy 16 view events
Omalizumab Perinatal depression 13 view events
Omalizumab Urinary incontinence 13 view events
Omalizumab Concomitant disease aggravated 12 view events
Omalizumab Gestational diabetes 12 view events
Omalizumab Gestational hypertension 12 view events
Omalizumab Hypoxia 12 view events
Omalizumab Nasal polyps 12 view events
Omalizumab Pharyngitis 12 view events
Omalizumab Premature labour 12 view events
Omalizumab Rhinitis allergic 12 view events
Omalizumab Anaemia 11 view events
Omalizumab Blood magnesium decreased 11 view events
Omalizumab Hypothyroidism 11 view events
Omalizumab Postural orthostatic tachycardia syndrome 11 view events

Total Drug/Injury Combinations: 175     Number of Pages: 9

NOTE: EventCount numbers on this page include duplicate entries from event reports. (e.g. One event has DrugX entered twice, which equals 2 on this page.) The "view events" page treats these duplicates as single entries. (e.g. The 2 entries of DrugX for a single event are counted as 1 instance.)